Soltys Scott G, Adler John R, Lipani John D, Jackson Paul S, Choi Clara Y H, Puataweepong Putipun, White Scarlett, Gibbs Iris C, Chang Steven D
Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA, USA.
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):187-93. doi: 10.1016/j.ijrobp.2007.06.068. Epub 2007 Sep 19.
The purpose of this study was to analyze results of adjuvant stereotactic radiosurgery (SRS) targeted at resection cavities of brain metastases without whole-brain irradiation (WBI).
Patients who underwent SRS to the tumor bed, deferring WBI after resection of a brain metastasis, were retrospectively identified.
Seventy-two patients with 76 cavities treated from 1998 to 2006 met inclusion criteria. The SRS was delivered to a median marginal dose of 18.6 Gy (range, 15-30 Gy) targeting an average tumor volume of 9.8 cm(3) (range, 0.1-66.8 cm(3)). With a median follow-up of 8.1 months (range, 0.1-80.5 months), 65 patients had follow-up imaging assessable for control analyses. Actuarial local control rates at 6 and 12 months were 88% and 79%, respectively. On univariate analysis, increasing values of conformality indices were the only treatment variables that correlated significantly with improved local control; local control was 100% for the least conformal quartile compared with 63% for the remaining quartiles. Target volume, dose, and number of sessions were not statistically significant.
In this retrospective series, SRS administered to the resection cavity of brain metastases resulted in a 79% local control rate at 12 months. This value compares favorably with historic results with observation alone (54%) and postoperative WBI (80-90%). Given the improved local control seen with less conformal plans, we recommend inclusion of a 2-mm margin around the resection cavity when using this technique.
本研究旨在分析针对脑转移瘤切除腔进行辅助立体定向放射外科治疗(SRS)且不进行全脑照射(WBI)的结果。
回顾性确定那些在脑转移瘤切除后接受肿瘤床SRS治疗且推迟WBI的患者。
1998年至2006年期间,72例患者的76个切除腔符合纳入标准。SRS的中位边缘剂量为18.6 Gy(范围15 - 30 Gy),靶向平均肿瘤体积为9.8 cm³(范围0.1 - 66.8 cm³)。中位随访时间为8.1个月(范围0.1 - 80.5个月),65例患者有可用于对照分析的随访影像。6个月和12个月时的精算局部控制率分别为88%和79%。单因素分析显示,适形指数值增加是与局部控制改善显著相关的唯一治疗变量;最不适形四分位数组的局部控制率为100%,其余四分位数组为63%。靶体积、剂量和治疗次数无统计学意义。
在这个回顾性系列研究中,对脑转移瘤切除腔进行SRS治疗,12个月时的局部控制率为79%。该值与单纯观察的历史结果(54%)和术后WBI的结果(80 - 90%)相比更具优势。鉴于在不太适形的计划中观察到局部控制有所改善,我们建议在使用该技术时,在切除腔周围包含2 mm的边缘。